Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
Authors:
- Ruud van der NollRNRuud van der Noll
- Suzanne LeijenSLSuzanne Leijen
- Guido H.G. NeuteboomGNGuido H.G. Neuteboom
- Jos H. BeijnenJBJos H. Beijnen
- Jan H.M. SchellensJSJan H.M. Schellens
- 1 October 2013
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 39 (6) , 664-672
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Automated macular pathology diagnosis in retinal OCT images using multi-scale spatial pyramid and local binary patterns in texture and shape encodingMedical Image Analysis, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoBritish Journal of Cancer, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosisExperimental Eye Research, 2010
- Mitogen‐activated protein kinase‐signaling regulates the ability of Müller glia to proliferate and protect retinal neurons against excitotoxicityGlia, 2009
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- Mutations of the BRAF gene in human cancerNature, 2002